WordNet

a salt or ester of acetic acid (同)ethanoate
a synthetic progestational compound used to treat endometrial carcinoma (同)megestrol_acetate

PrepTutorEJDIC

酢酸(さくさん)塩;アセテート(酢酸人造絹糸)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/06/17 05:09:28」(JST)

wiki en

Megestrol acetate (INN, USAN, BAN, JAN; sold mainly under the brand names Megace and Megace ES), also known as 17α-acetoxy-6-dehydro-6-methylprogesterone, and sometimes abbreviated as MGA or MA, is a steroidal progestin and progesterone derivative (specifically, a 17-hydroxylated progesterone) with predominantly progestational and antigonadotropic effects.^[4]^[5]^[6]

Though sometimes referred to simply as megestrol, it is important to clarify that megestrol acetate is not the same as megestrol, which is a closely related but different compound.^[5]

Uses[edit]

Megestrol acetate is used mainly as an appetite stimulant in a variety of conditions and as an antineoplastic agent in the treatment of breast, endometrial, and prostate cancers.^[7] When given in relatively high doses, it can substantially increase appetite in most individuals, even those with advanced cancer, and is often used to boost appetite and induce weight gain in patients with cancer or HIV/AIDS-associated cachexia. It is also used as a contraceptive in combination with an estrogen at relatively low doses.

In addition to its use in humans, megestrol acetate has been used extensively in veterinary medicine in the treatment of medical conditions in cats and dogs.^[5]

Dosage[edit]

Megestrol acetate is available as 5 mg, 20 mg and 40 mg tablets. It is used at a dose of 5 mg in combination with an estrogen for contraception. Appetite stimulation is achieved with doses ranging from 20 mg to 40 mg three times a day, 30 minutes before meals. Doses used to treat cancer usually range from 160 mg to 800 mg.

Pharmacology[edit]

Megestrol acetate acts predominantly as a potent agonist of the progesterone receptor (PR) to exert its effects.^[8]

Megestrol acetate has powerful antiandrogenic and antiestrogenic effects in humans at sufficient doses, capable of decreasing circulating androgen and estrogen concentrations to castrate levels in both sexes and significantly lowering the expression of the androgen receptor (AR) and the estrogen receptor (ER) in the body;^[9]^[10]^[11]^[12]^[13] as an example, one study in men with benign prostatic hyperplasia who were treated with 120-160 mg of megestrol acetate per day for 3 to 11 days found average decreases in AR quantity of 73% and 86% in the cytoplasm and nucleus of prostatic cells, respectively.^[12] These actions are likely the result of a strong activation of the PR, which suppresses the secretion of the gonadotropins—peptide hormones responsible for signaling the body to produce not only progesterone but also the androgens and the estrogens—from the pituitary gland as a form of negative feedback inhibition, and hence downregulates the hypothalamic-pituitary-gonadal (HPG) axis, resulting in decreased levels of the sex hormones and their associated enzymes, carriers (e.g., sex hormone-binding globulin), and receptors.^[14] It is the antiandrogenic and antiestrogenic effects of megestrol acetate mediated by suppression of the HPG axis that are believed to be largely responsible for its beneficial effects against androgen and estrogen-sensitive cancers, respectively.^[15]^[16]

Megestrol acetate is a high-affinity, weak partial agonist/antagonist of the AR,^[17]^[18]^[19] where it binds with very similar but slightly less affinity relative to the PR (about 75% of the affinity according to one assay).^[8] However, at clinical doses in humans, it appears to behave, for all intents and purposes, purely as an antiandrogen. No androgenic side effects have been observed with the use of megestrol acetate in patients of either sex at doses up to as high as 1,600 mg per day (which is the highest that has been used).^[20] Furthermore, it produces detectable androgenic effects in animals only at a dose that is the equivalent of approximately 200 times that typically used for the treatment of prostate cancer in men.^[21]

Unlike the case of the AR, megestrol acetate has no significant affinity for the ER.^[8] As such, it does not possess the capacity to directly activate the ER. Furthermore, unlike conventional antiandrogens like cyproterone and flutamide, there is relatively little risk of indirectly-mediated estrogenic side effects (e.g., gynecomastia) with megestrol acetate.^[22] This is because conventional antiandrogens only suppress androgen activity (which, because androgen and estrogen activities are typically inversely proportional, results in heightened estrogen levels), whereas megestrol acetate suppresses both androgen and estrogen levels at the same time.

Megestrol acetate is an agonist of the glucocorticoid receptor, with similar but less affinity in comparison to the PR and the AR (about 37% and 50% of the affinity, respectively, according to one assay).^[8]^[19] One study found that, in the dose range tested, it possesses about 50% of the eosinopenic and hyperglycemic activity (markers of glucocorticoid activity) of an equal amount of medroxyprogesterone acetate, and about 25% that of cortisol.^[23] Accordingly, manifestations of its glucocorticoid properties, including symptoms of Cushing's syndrome, steroid diabetes, and adrenal insufficiency, have been reported with the use of megestrol acetate in the medical literature, albeit sporadically.^[24]

Megestrol acetate is frequently used as an appetite stimulant. The direct mechanism of appetite enhancement is unclear, but it is known that megestrol acetate induces a variety of downstream changes to cause the effect, including stimulation of the release of neuropeptide Y in the hypothalamus, modulation of calcium channels in the ventromedial hypothalamus, and inhibition of the secretion of proinflammatory cytokines including IL-1α, IL-1β, IL-6, and TNF-α, all of which have been implicated in facilitation of appetite.^[25]^[26]^[27]

Side effects[edit]

The most common side effect of megestrol acetate is weight gain. Other side effects may include nausea, vomiting, impotence, edema, breakthrough bleeding, and shortness of breath. Rare and more severe side effects may include thrombophlebitis and pulmonary embolism.^[2] It may also cause glucocorticoid-related adverse effects such as adrenal insufficiency in some individuals and/or cases (especially if the medication is suddenly discontinued following prolonged use).^[28]^[29]

Contraindications[edit]

Megestrol acetate should not be used in pregnancy under any circumstance as it crosses the placenta and malignantly affects the fetus.^[30]

References[edit]

^ ^a ^b Schindler AE, Campagnoli C, Druckmann R, et al. (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 Suppl 1: S7–S16. PMID 14670641.
^ ^a ^b Richard R. Barakat; Maurie Markman; Marcus Randall (29 May 2009). Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins. p. 447. ISBN 978-0-7817-7845-9. Retrieved 2 June 2012.
^ Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 173. ISBN 978-0-7514-0499-9. Retrieved 2 June 2012.
^ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1267. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.
^ ^a ^b ^c Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 641. ISBN 978-3-88763-075-1. Retrieved 2 June 2012.
^ Neumann F (1978). "The physiological action of progesterone and the pharmacological effects of progestogens--a short review". Postgraduate Medical Journal. 54 Suppl 2: 11–24. PMID 368741.
^ Kenneth L. Becker (24 April 2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. p. 1195. ISBN 978-0-7817-1750-2. Retrieved 27 May 2012.
^ ^a ^b ^c ^d Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J (July 1980). "Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer". Cancer Research 40 (7): 2557–61. PMID 6248208.
^ Geller J, Albert J, Yen SS, Geller S, Loza D (March 1981). "Medical castration of males with megestrol acetate and small doses of diethylstilbestrol". The Journal of Clinical Endocrinology and Metabolism 52 (3): 576–80. PMID 6161942.
^ Venner PM (December 1990). "Therapeutic options in treatment of advanced carcinoma of the prostate". Seminars in Oncology 17 (6 Suppl 9): 73–7. PMID 2259929.
^ Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinnsland S (June 1990). "Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings". Journal of Steroid Biochemistry 36 (1-2): 99–104. PMID 2362454.
^ ^a ^b Geller J, Albert J, Geller S (1982). "Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue". The Prostate 3 (1): 11–5. PMID 6176985.
^ Blumenschein GR (December 1983). "The role of progestins in the treatment of breast cancer". Seminars in Oncology 10 (4 Suppl 4): 7–10. PMID 6230722.
^ Alexieva-Figusch J, Blankenstein MA, de Jong FH, Lamberts SW (September 1984). "Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer". European Journal of Cancer & Clinical Oncology 20 (9): 135–40. PMID 6434315.
^ Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (March 1989). "Megestrol acetate: clinical experience". Cancer Treatment Reviews 16 (1): 49–63. PMID 2471590.
^ Sedlacek SM (April 1988). "An overview of megestrol acetate for the treatment of advanced breast cancer". Seminars in Oncology 15 (2 Suppl 1): 3–13. PMID 3285483.
^ Eil C, Edelson SK (July 1984). "The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors". The Journal of Clinical Endocrinology and Metabolism 59 (1): 51–5. PMID 6725525.
^ Luthy IA, Begin DJ, Labrie F (November 1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry 31 (5): 845–52. PMID 2462135.
^ ^a ^b Poyet P, Labrie F (October 1985). "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate". Molecular and Cellular Endocrinology 42 (3): 283–8. PMID 3930312.
^ Farrar DJ (March 1999). "Megestrol acetate: promises and pitfalls". AIDS Patient Care and STDs 13 (3): 149–52. PMID 10375262.
^ Tisell LE, Salander H (February 1975). "Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats". Acta Endocrinologica 78 (2): 316–24. PMID 1172901.
^ Kenneth A. Foon (1998). Biological and Hormonal Therapies of Cancer. Springer. p. 73. ISBN 978-0-7923-9997-1. Retrieved 2 June 2012.
^ Briggs MH, Briggs M (October 1973). "Glucocorticoid properties of progestogens". Steroids 22 (4): 555–9. PMID 4747450.
^ Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M (1997). "Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature". Archives of Internal Medicine 157 (15): 1651–6. PMID 9250225.
^ Ann M. Berger; John L. Shuster; Jamie H. Von Roenn (6 October 2006). Principles And Practice of Palliative Care And Supportive Oncology. Lippincott Williams & Wilkins. p. 128. ISBN 978-0-7817-9595-1. Retrieved 27 May 2012.
^ Achim Jörres (19 February 2010). Management of Acute Kidney Problems. Springer. p. 210. ISBN 978-3-540-69413-7. Retrieved 27 May 2012.
^ David S. Ettinger (11 November 2008). Supportive Care in Cancer Therapy. Springer. p. 61. ISBN 978-1-58829-941-3. Retrieved 27 May 2012.
^ Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (February 2006). "High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate". Journal of Endocrinological Investigation 29 (2): 136–40. PMID 16610239.
^ Bulchandani D, Nachnani J, Amin A, May J (August 2008). "Megestrol acetate-associated adrenal insufficiency". The American Journal of Geriatric Pharmacotherapy 6 (3): 167–72. doi:10.1016/j.amjopharm.2008.08.004. PMID 18775392.
^ http://www.answers.com/topic/megestrol-megace

Raney MS, Anding R, Fay V, Polk G (2000). "A pilot study to assess the use of megesterol acetate to promote weight gain in frail elderly persons residing in long-term care". J Am Med Dir Assoc 1 (4): 154–8. PMID 12816553.
Deutsch J, Kolhouse JF (July 2004). "Assessment of gastrointestinal function and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss". Support Care Cancer 12 (7): 503–10. doi:10.1007/s00520-004-0615-4. PMID 15064933.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 子宮内膜増殖症の管理 management of endometrial hyperplasia
2. 高齢者における衰弱：管理 failure to thrive in elderly adults management
3. 癌における食欲不振および悪液質の薬理学的管理 pharmacologic management of cancer anorexia cachexia
4. 高齢者の栄養：高齢者における栄養上の問題 geriatric nutrition nutritional issues in older adults
5. HIV感染患者における組織の消耗の管理 management of tissue wasting in patients with hiv infection

English Journal

Treatment of Cachexia: An Overview of Recent Developments.

von Haehling S1, Anker SD2.
Journal of the American Medical Directors Association.J Am Med Dir Assoc.2014 Dec;15(12):866-872. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20.
Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body w
PMID 25455531

Tolerability and Pharmacokinetics of Two Formulations of Megestrol Acetate under Fed Conditions in Healthy Volunteers.

Kim YH1, Choi HY1, Jin S1, Noh YH2, Kim MJ1, Park HJ3, Lim HS1, Bang K4, Lee SH4, Bae KS5.
Clinical therapeutics.Clin Ther.2014 Oct 23. pii: S0149-2918(14)00614-6. doi: 10.1016/j.clinthera.2014.09.022. [Epub ahead of print]
PURPOSE: Megestrol acetate oral suspension is an appetite stimulant indicated for cachexia. It is available in a conventional formulation and as a nanocrystal dispersion. The aim of this study was to compare the tolerability and pharmacokinetics of these formulations under fed conditions in healthy
PMID 25450470

Pharmacologic management of human immunodeficiency virus wasting syndrome.

Badowski M1, Pandit NS.
Pharmacotherapy.Pharmacotherapy.2014 Aug;34(8):868-81. doi: 10.1002/phar.1431. Epub 2014 Apr 30.
Pharmacologic interventions for human immunodeficiency virus (HIV) wasting have been studied since the 1990s, but the results of these interventions have been difficult to compare because the studies used different HIV wasting definitions and assessed various patient outcomes. Thus, we performed a s
PMID 24782295

Japanese Journal

A case of treatment using high-dose Megestrol Acetate (Megace) combined with PDT (Photodynamic Therapy) at an early stage of endometrial carcinoma, in nulliparous woman(Oncology 11)

Ahn T-G.,Choi B-C.,Sokolov V.,Ahn W-S.,Han S-J.
日本産科婦人科學會雜誌 57(2), 804, 2005-02-01
NAID 110004038303

Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients

WEISBERG J.
Chest 121, 1070-1078, 2002
NAID 30006861020

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment

BERNHARD J.
Eur J Cancer 35, 913-920, 1999
NAID 30003888632

Related Pictures

★リンクテーブル★

リンク元	「メゲストロール」「酢酸メゲストロール」

「メゲストロール」

Megestrol acetate
Systematic (IUPAC) name
	17-(acetyloxy)-6-methyl-pregna-4,6-diene-3,20-dione
Clinical data
Pregnancy cat.	X (US)
Legal status	℞ Prescription only
Routes	Oral
Pharmacokinetic data
Bioavailability	100% (oral)
Protein binding	Yes (to albumin, but not to sex hormone-binding globulin or transcortin)
Half-life	13 to 105 hours (mean 34 hours)
Identifiers
CAS number	3562-63-8
ATC code	G03AC05
PubChem	CID 11683
DrugBank	DB00351
ChemSpider	11192
Synonyms	BDH-1298, NSC-71423
Chemical data
Formula	C24H32O4
Mol. mass	384.509 g/mol
	SMILES O=C4\C=C3\C(=C/[C@@H]1[C@H](CC[C@@]2([C@@](OC(=O)C)(C(=O)C)CC[C@@H]12)C)[C@@]3(C)CC4)C;
	InChI InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1; Key:RQZAXGRLVPAYTJ-GQFGMJRRSA-N ;

　　[★]

英: megestrol
関: 酢酸メゲストロール megestrol acetate

「酢酸メゲストロール」

　　[★]

英: megestrol acetate
関: メゲストロール

[pmid14670641-1] Schindler AE, Campagnoli C, Druckmann R, et al. (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 Suppl 1: S7–S16. PMID 14670641.

[BarakatMarkman2009-2] Richard R. Barakat; Maurie Markman; Marcus Randall (29 May 2009). Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins. p. 447. ISBN 978-0-7817-7845-9. Retrieved 2 June 2012.

[MortonMorton1999-3] Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 173. ISBN 978-0-7514-0499-9. Retrieved 2 June 2012.

[Macdonald1997-4] F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1267. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.

[Index_Nominum_2000:_International_Drug_Directory-5] Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 641. ISBN 978-3-88763-075-1. Retrieved 2 June 2012.

[pmid368741-6] Neumann F (1978). "The physiological action of progesterone and the pharmacological effects of progestogens--a short review". Postgraduate Medical Journal. 54 Suppl 2: 11–24. PMID 368741.

[Becker2001-7] Kenneth L. Becker (24 April 2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. p. 1195. ISBN 978-0-7817-1750-2. Retrieved 27 May 2012.

[pmid6248208-8] Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J (July 1980). "Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer". Cancer Research 40 (7): 2557–61. PMID 6248208.

[pmid6161942-9] Geller J, Albert J, Yen SS, Geller S, Loza D (March 1981). "Medical castration of males with megestrol acetate and small doses of diethylstilbestrol". The Journal of Clinical Endocrinology and Metabolism 52 (3): 576–80. PMID 6161942.

[pmid2259929-10] Venner PM (December 1990). "Therapeutic options in treatment of advanced carcinoma of the prostate". Seminars in Oncology 17 (6 Suppl 9): 73–7. PMID 2259929.

[pmid2362454-11] Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinnsland S (June 1990). "Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings". Journal of Steroid Biochemistry 36 (1-2): 99–104. PMID 2362454.

[pmid6176985-12] Geller J, Albert J, Geller S (1982). "Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue". The Prostate 3 (1): 11–5. PMID 6176985.

[pmid6230722-13] Blumenschein GR (December 1983). "The role of progestins in the treatment of breast cancer". Seminars in Oncology 10 (4 Suppl 4): 7–10. PMID 6230722.

[pmid6434315-14] Alexieva-Figusch J, Blankenstein MA, de Jong FH, Lamberts SW (September 1984). "Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer". European Journal of Cancer & Clinical Oncology 20 (9): 135–40. PMID 6434315.

[pmid2471590-15] Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (March 1989). "Megestrol acetate: clinical experience". Cancer Treatment Reviews 16 (1): 49–63. PMID 2471590.

[pmid3285483-16] Sedlacek SM (April 1988). "An overview of megestrol acetate for the treatment of advanced breast cancer". Seminars in Oncology 15 (2 Suppl 1): 3–13. PMID 3285483.

[pmid6725525-17] Eil C, Edelson SK (July 1984). "The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors". The Journal of Clinical Endocrinology and Metabolism 59 (1): 51–5. PMID 6725525.

[pmid2462135-18] Luthy IA, Begin DJ, Labrie F (November 1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry 31 (5): 845–52. PMID 2462135.

[pmid3930312-19] Poyet P, Labrie F (October 1985). "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate". Molecular and Cellular Endocrinology 42 (3): 283–8. PMID 3930312.

[pmid10375262-20] Farrar DJ (March 1999). "Megestrol acetate: promises and pitfalls". AIDS Patient Care and STDs 13 (3): 149–52. PMID 10375262.

[pmid1172901-21] Tisell LE, Salander H (February 1975). "Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats". Acta Endocrinologica 78 (2): 316–24. PMID 1172901.

[Foon1998-22] Kenneth A. Foon (1998). Biological and Hormonal Therapies of Cancer. Springer. p. 73. ISBN 978-0-7923-9997-1. Retrieved 2 June 2012.

[pmid4747450-23] Briggs MH, Briggs M (October 1973). "Glucocorticoid properties of progestogens". Steroids 22 (4): 555–9. PMID 4747450.

[pmid9250225-24] Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M (1997). "Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature". Archives of Internal Medicine 157 (15): 1651–6. PMID 9250225.

[BergerShuster2006-25] Ann M. Berger; John L. Shuster; Jamie H. Von Roenn (6 October 2006). Principles And Practice of Palliative Care And Supportive Oncology. Lippincott Williams & Wilkins. p. 128. ISBN 978-0-7817-9595-1. Retrieved 27 May 2012.

[J.C3.B6rres2010-26] Achim Jörres (19 February 2010). Management of Acute Kidney Problems. Springer. p. 210. ISBN 978-3-540-69413-7. Retrieved 27 May 2012.

[Ettinger2008-27] David S. Ettinger (11 November 2008). Supportive Care in Cancer Therapy. Springer. p. 61. ISBN 978-1-58829-941-3. Retrieved 27 May 2012.

[pmid16610239-28] Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (February 2006). "High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate". Journal of Endocrinological Investigation 29 (2): 136–40. PMID 16610239.

[pmid18775392-29] Bulchandani D, Nachnani J, Amin A, May J (August 2008). "Megestrol acetate-associated adrenal insufficiency". The American Journal of Geriatric Pharmacotherapy 6 (3): 167–72. doi:10.1016/j.amjopharm.2008.08.004. PMID 18775392.

[30] ttp://www.answers.com/topic/megestrol-megace

匿名

検索

案内

案内

megestrol acetate